- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02741375
Cerebral Oximetry As an Auxiliary Diagnostic Tool in the Diagnosis of Brain Death
Aim: To investigate the efficacy of cerebral oximetry (CO) as an auxiliary diagnostic tool in confirming brain death (BD).
Materials and Methods: This observational and interventional study was performed on patients with suspected BD in emergency departments and intensive care units. CO monitoring was performed for at least 6 h, and cerebral tissue oxygen saturation (ScO2) was recorded. Basal ScO2 values (basal ScO2), ScO2 values after 6 h (end ScO2), mean ScO2 values during monitoring (mean ScO2), and minimum (min ScO2) and maximum (max ScO2) ScO2 values observed during monitoring were recorded for all patients. Patients with diagnosis of BD confirmed by the organ transplantation and brain death committee were enrolled as the BD group and other patients as the non-BD group, and cerebral oxygen parameters were compared.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Brain death (BD) means the irreversible loss of all brain and brain stem functions and physiopathologically the cessation of intracranial circulation. BD is a clinical diagnosis that can be made with various clinical tests. However, in order for BD to be definitely established, clinical tests performed initially need to be repeated after 24 h or to be confirmed by corroboratory tests. In addition, the obligation to confirm BD using corroboratory tests varies in current guidelines from country to country but has been eliminated except for certain specific circumstances. However, considering the adverse effects on patients awaiting donor and organ donations of the time lapse between initial and repeat tests in order to confirm BD, more rapid confirmation of definite BD is commonly made using corroboratory tests.
This study was planned with the hypothesis that this non-invasive technique using NIRS technology can be an auxiliary tool in the diagnosis of BD.
This study was performed with patients with suspected BD in emergency departments and intensive care units and was intended to evaluate the effectiveness of cerebral oximetry as an auxiliary diagnostic tool in patients with suspected BD.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Trabzon, Turkey, 61080
- Karadeniz Technical University Faculty of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients monitored and treated in the emergency department of intensive care units with a GCS score of 3 and evaluated as brain-dead at consultation with the Organ Transplantation Brain Death Committee on suspicion of BD
- Aged over 18 years
Exclusion Criteria:
- Cause of coma being undetermined
- Lack of confirmation of brain injury being diffuse and irreversible
- Central body temperature being lower than 32°C
- Presence of a picture of hypotensive shock
- Coma after drug effects and intoxications
- Presence of metabolic, electrolyte or acid-alkaline disorders
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Brain Death Group (BD group)
Patients assessed as brain-dead at the first clinical evaluation by the OTBD committee were definitively diagnosed with BD through repeat clinical evaluation after 24 h or through CT angiography as a corroboratory test.
Patients regarded as definitely brain-dead on the basis of this evaluation were classified as the BD group.
|
All patients underwent at least 6-h NIRS monitoring using a Somanetics 5100c (Invos oximeter cerebral/somatic Troy, MI, USA) cerebral oximeter in order to determined cerebral oximetry changes.
|
|
Non-Brain Death Group (Non BD group)
Patients assessed as brain-dead at the first clinical evaluation by the OTBD committee were definitively diagnosed with BD through repeat clinical evaluation after 24 h or through CT angiography as a corroboratory test.
Patients regarded as definitely not brain-dead on the basis of this evaluation were classified as the non-BD group.
|
All patients underwent at least 6-h NIRS monitoring using a Somanetics 5100c (Invos oximeter cerebral/somatic Troy, MI, USA) cerebral oximeter in order to determined cerebral oximetry changes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Basal ScO2 (Cerebral oxygen saturation) (%)
Time Frame: Measured at the beginning of 6 hours cerebral oximetry monitoring
|
Measured at the beginning of 6 hours cerebral oximetry monitoring
|
|
End ScO2 (Cerebral oxygen saturation) (%)
Time Frame: Measured at the end of 6 hours cerebral oximetry monitoring
|
Measured at the end of 6 hours cerebral oximetry monitoring
|
|
Mean ScO2 (Cerebral oxygen saturation) (%)
Time Frame: Measured during 6 hours cerebral oximetry monitoring
|
Measured during 6 hours cerebral oximetry monitoring
|
|
Min ScO2 (Cerebral oxygen saturation) (%)
Time Frame: Measured during 6 hours cerebral oximetry monitoring
|
Measured during 6 hours cerebral oximetry monitoring
|
|
Max ScO2 (Cerebral oxygen saturation) (%)
Time Frame: Measured during 6 h cerebral oximetry monitoring
|
Measured during 6 h cerebral oximetry monitoring
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Decrease in ScO2
Time Frame: Measured during 6 hours cerebral oximetry monitoring
|
Difference between basal ScO2 and end ScO2
|
Measured during 6 hours cerebral oximetry monitoring
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014/05
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.